Clinical Trial Update: Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of two MF59C.1-adjuvanted influenza vaccines given in two doses three weeks apart in non-elderly and elderly …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Pandemic

Drugs mentioned

• Influenza vaccine MF59C.1-adjuvanted (Vaccine A) (Influenza vaccine MF59C.1-adjuvanted)
• Influenza vaccine MF59C.1-adjuvanted (Vaccine B) (Influenza vaccine MF59C.1-adjuvanted)

Snippet

Sponsor: Novartis | Conditions: Pandemic Influenza Disease | Phase 2 | Status: COMPLETED